Hong Zhu
Zhejiang University
384 Papers
1.1K Citations
Hong Zhu is an academic researcher from Zhejiang University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 49, co-authored 323 publications. Previous affiliations of Hong Zhu include Center for Excellence in Education & Shanghai Jiao Tong University.
Chat about Author
Papers
Patent
Application of YOD1 gene in preparation of leukemia induced differentiation treatment drug
Meidan Ying,He Qiaojun,Yang Bo,Xuejing Shao,Yingqian Chen,Ji Cao,Hong Zhu +6 more
- 10 Jul 2020
TL;DR: In this paper, a siRNA interference technology was used to induce differentiation of leukemia NB4 cells by reducing expression of YOD1, and a new treatment target for induced differentiation treatment of leukemia was provided.
Analog, Traps Topoisomerase II Cleavage Complexes and Exerts Anticancer Activities 1
Xiaochun Yang,Shijing Qian,Li Wang,Si-Da Liao,Ji Cao,Yong-Zhou Hu,Qiao-Jun He,Hong Zhu,Bo Yang,Normole Superienre +9 more
- 01 Jan 2013
TL;DR: Among a series of 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin analogs, GL3 stood out by its improved anticancer activity and well-defined Top 2 poisoning mechanisms, which merited the potential value of GL3 as an anticancer lead compound/drug candidate deserving further development.
Patent
Application of JOSD2 protein in preparation of drug for treating malignant tumors
Yang Bo,He Qiaojun,Hong Zhu,Ji Cao,Chen-Ming Zeng +4 more
- 12 May 2020
TL;DR: In this paper, a JOSD2 protein was used for diagnosing malignant tumors and predicting prognosis of malignant tumor, and a new and effective target treatment drug was provided.
Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.
Hong Zhu,Wei Yang,Ling-juan He,Wanjing Ding,Lin Zheng,Si-Da Liao,Ping Huang,Wei Lu,Qiaojun He,Bo Yang +9 more
TL;DR: This study demonstrated that combining ABT-737 and Celastrol synergistically suppressed HCC cell proliferation, and induced apoptosis which was accompanied with the activation of caspase cascade and release of cytochrome c from mitochondria, and suggested the potential use of ATF4-mediated regulation of Noxa as a promising strategy to improve the anti-cancer activities of ABT.
Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Min Huang,Heyong Gao,Yi Chen,Hong Zhu,Yu-Jun Cai,Xiongwen Zhang,Ze-Hong Miao,Hualiang Jiang,Jian Zhang,Hong Wu Shen,Liping Lin,Wei Lu,Jian Ding +12 more
TL;DR: The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and oral availability, which might favorably promise its therapeutic potential in clinical settings.